Actively Recruiting
Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
Led by University Hospital, Toulouse · Updated on 2026-05-11
34
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project will explore the involvement of the serotonin system in the pathophysiology of PD-related central pain. Thus, the serotonin system will be evaluated in PD patients with and without central pain who will benefit from brain positron emission tomography (PET) allowing in vivo imaging of 5HT1A receptors and multimodal brain MRI including morphometric imaging and functional connectivity (resting state acquisition).
CONDITIONS
Official Title
Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with Parkinson's Disease using UK Parkinson's Disease Brain Bank criteria
- Patients on stable anti-parkinsonian treatment for at least 4 weeks before joining
- Montreal Cognitive Assessment (MoCA) score greater than 25
- Hospital Anxiety and Depression Scale (HADS)-D score of 11 or higher
- Patients affiliated with or benefiting from a social security scheme
- Signed free, informed, and written consent before any study examination
- For patients with pain: diagnosed with PD-related central pain per Marques et al. 2019 criteria
- For patients with pain: chronic central pain lasting at least 3 months
- For patients with pain: average pain score of 4 or higher on the Visual Analog Scale (VAS) over the past month
- For patients without pain: pain score of 4 or lower on the VAS, indicating pain does not affect daily activity
You will not qualify if you...
- Use of second line therapy
- History of significant psychiatric illness as judged by the investigator
- Use of drugs affecting 5HT1A receptors within the last 4 weeks
- Contraindications to MRI scanning
- Refusal to be informed of any abnormalities found during brain imaging
- Disabling dyskinesias as judged by the investigator that interfere with imaging
- Under legal guardianship, other legal protection, or deprived of liberty by judicial or administrative decision
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire de Toulouse
Toulouse, Haute-Garonne, France, 31000
Actively Recruiting
Research Team
C
Christine BREFEL-COURBON, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here